WB
H
Endogenous
28
Rabbit
#P40261
4837
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu12 of human NNMT protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Nicotinamide N-methyltransferase (NNMT) is a metabolic enzyme expressed primarily in liver and adipose tissue. It catalyzes the transfer of a methyl group from S-Adenosyl-methionine (SAM) to nicotinamide, yielding 1-methylnicotinamide (MNAM) and S-Adenosyl-L-homocysteine (SAH) (1). This N-methylation enzymatic activity plays an important role in the biotransformation of drugs and xenobiotics, and also contributes to the metabolism of vitamin B3 (2). Knockdown of NNMT was shown to increase both SAM and NAD+ levels in white adipose tissue of high-fat diet-fed mice, resulting in increased energy expenditure and protection against diet-induced obesity (3). In contrast, increased liver NNMT expression in humans and mice correlated with an improved metabolic profile, through MNAM-mediated SIRT1 protein stabilization (4). In cancer cells, overexpression of NNMT resulted in excess consumption of methyl units from SAM, leading to histone hypomethylation that substantially altered the epigenetic landscape (5). These and other research studies have suggested that NNMT expression may have utility as a diagnostic and prognostic biomarker in cancer (6-8).
- Aksoy, S. et al. (1994) J Biol Chem 269, 14835-40.
- Pissios, P. (2017) Trends Endocrinol Metab 28, 340-53.
- Kraus, D. et al. (2014) Nature 508, 258-62.
- Hong, S. et al. (2015) Nat Med 21, 887-94.
- Ulanovskaya, O.A. et al. (2013) Nat Chem Biol 9, 300-6.
- Xu, Y. et al. (2016) Oncotarget 7, 19975-81.
- Mascitti, M. et al. (2019) Melanoma Res 29, 151-6.
- Ganzetti, G. et al. (2018) Melanoma Res 28, 82-8.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.